CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death

Blood

Volumn 118, Issue 23, 2011, Pages 6141-6152

  Serra, Sara ^a   Horenstein, Alberto L ^b   Vaisitti, Tiziana ^a   Brusa, Davide ^a   Rossi, Davide ^c   Laurenti, Luca ^d   D'Arena, Giovanni ^e   Coscia, Marta ^f   Tripodo, Claudio ^g   Inghirami, Giorgio ^h   Robson, Simon C ⁱ   Gaidano, Gianluca ^c   Malavasi, Fabio ^b   Deaglio, Silvia ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

^h Centre for Molecular Biotechnology   (Italy)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5' NUCLEOTIDASE; ADENOSINE; ADENOSINE DIPHOSPHATE; CD39 ANTIGEN; ETOPOSIDE; EXTRACELLULAR ADENOSINE; KI 67 ANTIGEN; PROTEIN KINASE ZAP 70; PURINERGIC RECEPTOR; PURINERGIC RECEPTOR 1; PURINERGIC RECEPTOR 1 A2A; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; AUTOCRINE EFFECT; CELL ACTIVATION; CELL DEATH; CELL EXPANSION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG INDUCED CELL DEATH; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; LYMPH NODE; PARACRINE EFFECT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL NICHE; T LYMPHOCYTE; TUMOR CELL;

EID: 82955217840     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-374728     Document Type: Article

References (56)

1. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371(9617):1017-1029. (Pubitemid 351389535)
2. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol. 2007; 20(3):399-413. (Pubitemid 47250501)
3. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood. 2011;117(6):1781-1791.
4. Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol. 2008;26(27):4497-4503.
5. Soma LA, Craig FE, Swerdlow SH. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol. 2006;37(2): 152-159. (Pubitemid 43099834)
6. Patten PE, Buggins AG, Richards J, et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood. 2008;111(10):5173-5181.
7. Wickremasinghe RG, Ganeshaguru K, Jones DT, et al. Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in Bchronic lymphocytic leukaemia cells. Br J Haematol. 2001;114(3):608-615. (Pubitemid 32953639)
8. Seiffert M, Schulz A, Ohl S, Dohner H, Stilgenbauer S, Lichter P. Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood. 2010;116(20): 4223-4230.
9. Di Virgilio F, Boeynaems JM, Robson SC. Extracellular nucleotides as negative modulators of immunity. Curr Opin Pharmacol. 2009;9(4):507- 513.
10. Burnstock G. Unresolved issues and controversies in purinergic signalling. J Physiol (London). 2008;586(14):3307-3312. (Pubitemid 352005793)
11. Burnstock G, Verkhratsky A. Evolutionary origins of the purinergic signalling system. Acta Physiol. 2009;195(4):415-447.
12. Resta R, Yamashita Y, Thompson LF. Ectoenzyme and signaling functions of lymphocyte CD73. Immunol Rev. 1998;161:95-109.
13. Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25(1):33-39. (Pubitemid 38032805)
14. Sitkovsky MV, Ohta A. The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol. 2005;26(6):299-304. (Pubitemid 40732662)
15. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257-1265. (Pubitemid 46919862)
16. Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of ectonucleotidase CD39 by Foxp3+Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110(4):1225- 1232.
17. Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol. 2010; 185(4):1993-1998.
18. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One. 2008; 3(7):e2599.
19. Ohta A, Gorelik E, Prasad SJ, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A. 2006;103(35): 13132-13137. (Pubitemid 44338928)
20. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene. 2010;29(39):5346-5358.
21. Mikhailov A, Sokolovskaya A, Yegutkin GG, et al. CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis. J Immunol. 2008;181(1):464-475.
22. Stagg J, Divisekera U, McLaughlin N, et al. Anti- CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A. 2010;107(4):1547-1552.
23. Wang L, Fan J, Thompson LF, et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest. 2011;121(6):2371-2382.
24. Audrito V, Vaisitti T, Rossi D, et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res. 2011;71(13):4473- 4483.
25. Vaisitti T, Aydin S, Rossi D, et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia. 2010;24: 958-969.
26. Marcus AJ, Broekman MJ, Drosopoulos JH, et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest. 1997;99(6):1351-1360. (Pubitemid 27142773)
27. Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7(9):759-770.
28. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107(5):1761-1767. (Pubitemid 43289351)
29. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011; 11(3):201-212.
30. By Y, Durand-Gorde JM, Condo J, et al. Monoclonal antibody-assisted stimulation of adenosine A2A receptors induces simultaneous downregulation of CXCR4 and CCR5 on CD4+ T-cells. Hum Immunol. 2010;71(11):1073-1076.
31. Naderi EH, Findley HW, Ruud E, Blomhoff HK, Naderi S. Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation. Blood. 2009;114(3):608-618.
32. Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigenexperienced B lymphocytes. Blood. 2002;99(11): 4087-4093. (Pubitemid 35332051)
33. Rosi F, Tabucchi A, Carlucci F, et al. 5′-nucleotidase activity in lymphocytes from patients affected by Bcell chronic lymphocytic leukemia. Clin Biochem. 1998;31(4):269-272. (Pubitemid 28285359)
34. Pulte D, Furman RR, Broekman MJ, et al. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011;11(4):367-372.
35. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood. 2011; 118(13):3470-3478.
36. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulinvariable- region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764- 1775.
37. Richardson SJ, Matthews C, Catherwood MA, et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2006;107(9):3584-3592.
38. Takedachi M, Qu D, Ebisuno Y, et al. CD73- generated adenosine restricts lymphocyte migration into draining lymph nodes. J Immunol. 2008; 180(9):6288-6296.
39. Goepfert C, Sundberg C, Sevigny J, et al. Disordered cellular migration and angiogenesis in cd39-null mice. Circulation. 2001;104(25):3109- 3115.
40. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 1997;57(13):2602-2605. (Pubitemid 27283766)
41. Borrione P, Peola S, Mariani S, et al. CD38 stimulation lowers the activation threshold and enhances the alloreactivity of cord blood T cells by activating the phosphatidylinositol 3-kinase pathway and inducing CD73 expression. J Immunol. 1999;162(10):6238-6246. (Pubitemid 29314988)
42. Clark RR, Soutar DS. Lymph node metastases from auricular squamous cell carcinoma. A systematic review and meta-analysis. J Plast Reconstr Aesthet Surg. 2008;61(10):1140-1147.
43. Hilchey SP, Kobie JJ, Cochran MR, et al. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness. J Immunol. 2009;183(10):6157-6166.
44. Devereux S. Two-faced T cells in CLL. Blood. 2011;117(20):5273-5274.
45. Salmi M, Jalkanen S. Cell-surface enzymes in control of leukocyte trafficking. Nat Rev Immunol. 2005;5(10):760-771. (Pubitemid 41400850)
46. Färber K, Markworth S, Pannasch U, et al. The ectonucleotidase cd39/ENTPDase1 modulates purinergic-mediated microglial migration. Glia. 2008;56(3):331-341.
47. Williams AJ, Cronstein BN. The effect of A(2A) Adenosine receptor activation on C-C Chemokine receptor 7 expression in human THP1 macrophages during inflammation [published online ahead of print July 8, 2011]. Inflammation. doi: 10.1007/s10753-011-9353-1.
48. Zhang N, Yang D, Dong H, et al. Adenosine A2a receptors induce heterologous desensitization of chemokine receptors. Blood. 2006;108(1):38-44. (Pubitemid 43990610)
49. Jacobson KA, Hoffmann C, Cattabeni F, Abbracchio MP. Adenosine-induced cell death: evidence for receptor-mediated signalling. Apoptosis. 1999;4(3):197-211. (Pubitemid 29378788)
50. Apasov S, Chen JF, Smith P, Sitkovsky M. A(2A) receptor dependent and A(2A) receptor independent effects of extracellular adenosine on murine thymocytes in conditions of adenosine deaminase deficiency. Blood. 2000;95(12):3859-3867. (Pubitemid 30412861)
51. Himer L, Csoka B, Selmeczy Z, et al. Adenosine A2A receptor activation protects CD4+ T lymphocytes against activation-induced cell death. FASEB J. 2010;24(8):2631-2640.
52. Naderi A, Chia KM, Liu J. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13(2): R36.
53. Mackey JR, Galmarini CM, Graham KA, et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine- sensitive and -insensitive populations. Blood. 2005;105(2):767-774. (Pubitemid 40070764)
54. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15(6): 875-890. (Pubitemid 32529886)
55. Hauser RA, Cantillon M, Pourcher E, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011;10(3):221- 229.
56. Jin D, Fan J, Wang L, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010;70(6):2245-2255.